Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

@article{Thangavel2011TherapeuticallyAR,
  title={Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.},
  author={Chellappagounder Thangavel and Jeffry L. Dean and Adam Ertel and Karen E. Knudsen and C. Marcelo Aldaz and Agnieszka K. Witkiewicz and Robert Clarke and Erik S. Knudsen},
  journal={Endocrine-related cancer},
  year={2011},
  volume={18 3},
  pages={333-45}
}
The majority of estrogen receptor (ER)-positive breast cancers are treated with endocrine therapy. While this is effective, acquired resistance to therapies targeted against ER is a major clinical challenge. Here, model systems of ER-positive breast cancers with differential susceptibility to endocrine therapy were employed to define common nodes for new therapeutic interventions. These analyses revealed that cell cycle progression is effectively uncoupled from the activity and functional state… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 87 extracted citations

Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer

Annals of oncology : official journal of the European Society for Medical Oncology • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 57 references

American Society of Clinical Oncology / College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

TJ Harris, F McCormick
Journal of Clinical Oncology • 2010
View 3 Excerpts

Similar Papers

Loading similar papers…